Managing BPH: Lifestyle and Medication Options
At a Glance
BPH treatment is tailored to symptom severity, prostate size, and health history. Mild symptoms may be monitored with lifestyle changes, while medications can improve urine flow, shrink an enlarged prostate, or treat urgency; each option has specific side effects and safety precautions.
Managing Benign Prostatic Hyperplasia (BPH) is not a one-size-fits-all process. Your treatment plan will be personalized based on how much your symptoms bother you, your prostate size, your medical history, and your personal priorities [1][2].
For many men, treatment begins with simple adjustments to daily habits or medications that target the physical size of the prostate or the tension of the muscles within it.
Lifestyle Changes and Monitoring
If your symptoms are mild or do not significantly impact your quality of life, your doctor may recommend monitoring (watchful waiting) [1]. This involves periodic check-ups to ensure the condition isn’t progressing, paired with behavioral changes [3].
Effective lifestyle modifications often include:
- Fluid Management: Reducing fluid intake a few hours before bed to minimize nighttime trips (nocturia) [4][5]. Caution: Do not overly restrict fluids if you have kidney disease, and talk to your doctor first if you take diuretics (water pills) or have heart failure.
- Bladder Irritants: Limiting caffeine and alcohol, which can irritate the bladder and increase the urge to urinate [6].
- Double Voiding: After urinating, waiting a few moments and trying again to help empty the bladder [4]. Note: Never strain forcefully to push urine out.
Alpha-Blockers: Quick Symptom Relief
Alpha-blockers (such as tamsulosin, alfuzosin, and silodosin) are often the first medications prescribed [3][2]. They work by relaxing the smooth muscle in the prostate and the neck of the bladder.
- Speed of Action: Most men notice an improvement within a few days to a few weeks [7].
- Who They Are For: They improve flow and symptoms regardless of the prostate’s size, but they do not shrink the prostate or reliably prevent future urinary retention [3].
- Safety & Side Effects: Common side effects include dizziness and low blood pressure when standing (orthostatic hypotension), which can increase the risk of falls [8]. They frequently cause reduced or absent ejaculation [9].
- Crucial Warning for Eye Surgery: If you are planning cataract surgery, you must tell your eye surgeon you are taking or have taken tamsulosin or silodosin, as they can cause “Intraoperative Floppy Iris Syndrome.”
5-Alpha Reductase Inhibitors (5-ARIs): Shrinking the Gland
If your prostate is significantly enlarged, your doctor may recommend a 5-ARI like finasteride or dutasteride [7][10]. These medications block the hormones that signal the prostate to grow.
- Long-Term Prevention: Over time, they can shrink the gland by about 20% to 25%, significantly reducing the risk of sudden urinary retention and the need for future surgery [11][12].
- Slow Onset: It can take 6 to 12 months of daily use to see the full benefit [7].
- Side Effects: These may include decreased libido (sex drive), erectile dysfunction, or breast tenderness/enlargement [12].
- PSA Monitoring: These drugs lower your PSA test results by approximately 50%. Your doctor will use this rough adjustment to interpret your future PSA screenings for prostate cancer [7].
Combination Therapy
For men with larger prostates and a higher risk of progression, taking both an alpha-blocker and a 5-ARI is more effective than either drug alone [3][10]. However, this “dual approach” comes with the combined side effects of both medications, so it involves a trade-off [12].
Specialized Medical Options
PDE5 Inhibitors (Tadalafil)
Daily tadalafil (Cialis) relaxes the smooth muscles of the urinary tract and can be a good choice for men with both urinary symptoms and erectile dysfunction [13][14].
- Danger: Tadalafil must never be combined with nitrates (often used for chest pain) or riociguat. It requires careful medical supervision if you are also taking alpha-blockers or other blood-pressure medications.
Managing Urgency and Frequency
If you still have a strong, frequent urge to go, your doctor might add a “bladder-specific” drug:
- Antimuscarinics (e.g., Oxybutynin, Tolterodine): These help calm an overactive bladder. However, they carry a risk of causing urinary retention (especially if your bladder isn’t emptying well), as well as dry mouth, constipation, and potential cognitive effects in older adults [15].
- Beta-3 Agonists (e.g., Mirabegron): These can improve urgency with a slightly lower risk of urinary retention, but they can raise blood pressure and still require monitoring [16][15].
Finding the right medication plan requires ongoing communication with your doctor. If a medication isn’t working or the side effects are unmanageable, speak with your care team before stopping, as alternative treatments are available [17][18].
Common questions in this guide
Can lifestyle changes improve BPH symptoms?
When should I consider monitoring instead of BPH medication?
How soon do alpha-blockers relieve BPH symptoms?
How long do finasteride or dutasteride take to work for BPH?
Can BPH medicines affect sex or sexual function?
Is daily tadalafil safe if I have BPH and erectile dysfunction?
What can help BPH urgency and frequent urination?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my IPSS score and prostate size, am I a candidate for monitoring or should we discuss medication?
- 2.If we start an alpha-blocker, how soon should I expect to see an improvement in my symptoms?
- 3.Since 5-alpha reductase inhibitors can affect PSA levels, how will we adjust my results for cancer screening in the future?
- 4.I am concerned about sexual side effects—which of these medications has the lowest risk of affecting my libido or ejaculation?
- 5.If I have both urinary symptoms and erectile dysfunction, would daily tadalafil be a reasonable option for me?
- 6.Before adding a medication for my urgency symptoms, is my current post-void residual (PVR) low enough to avoid the risk of urinary retention?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Benign Prostatic Hyperplasia.
Langan RC
Primary care 2019; (46(2)):223-232 doi:10.1016/j.pop.2019.02.003.
PMID: 31030823 - 2
Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).
Anract J, Klein C, Sarrazin C, et al.
The French journal of urology 2025; (35(11)):102952 doi:10.1016/j.fjurol.2025.102952.
PMID: 41271371 - 3
How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW, Smith CC, Singla A, Libman H
Annals of internal medicine 2023; (176(4)):545-555 doi:10.7326/M23-0113.
PMID: 37037036 - 4
Lower Urinary Tract Symptoms in Men: A Review.
Wei JT, Dauw CA, Brodsky CN
JAMA 2025; (334(9)):809-821 doi:10.1001/jama.2025.7045.
PMID: 40658396 - 5
[Benign prostatic hyperplasia : New and treatment-relevant aspects from the DGU guidelines].
Bach T, Heitz M, Bruns T
Der Urologe. Ausg. A 2020; (59(5)):544-549 doi:10.1007/s00120-020-01184-y.
PMID: 32274543 - 6
Minimally invasive interventions for lower urinary tract symptoms: What sits between medical therapy and transurethral resection of the prostate.
Yanada BA, Homewood D, Reeves F, Bolton D
Australian journal of general practice 2024; (53(5)):258-263 doi:10.31128/AJGP-10-23-7007.
PMID: 38697056 - 7
[Pharmacological treatment of benign prostatic hyperplasia].
Oelke M, Martinelli E
Der Urologe. Ausg. A 2016; (55(1)):81-94; quiz 95-6 doi:10.1007/s00120-015-0011-3.
PMID: 26676726 - 8
Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement.
Osman T, Elawady H, Fawaz K, et al.
International urology and nephrology 2024; (56(6)):1811-1816 doi:10.1007/s11255-023-03912-7.
PMID: 38219259 - 9
[Sexual consequences of BPH treatments].
Descazeaud A, Robert G, de La Taille A
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2018; (28(15)):839-847 doi:10.1016/j.purol.2018.07.278.
PMID: 30195716 - 10
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
D'Agate S, Wilson T, Adalig B, et al.
World journal of urology 2020; (38(2)):463-472 doi:10.1007/s00345-019-02783-x.
PMID: 31079189 - 11
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
Kim EH, Brockman JA, Andriole GL
Asian journal of urology 2018; (5(1)):28-32 doi:10.1016/j.ajur.2017.11.005.
PMID: 29379733 - 12
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R, Strand DW, Forbes CM, et al.
The Prostate 2021; (81(13)):944-955 doi:10.1002/pros.24190.
PMID: 34288015 - 13
Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials.
Guo B, Chen X, Wang M, et al.
Medical science monitor : international medical journal of experimental and clinical research 2020; (26()):e923179 doi:10.12659/MSM.923179.
PMID: 32327621 - 14
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M, Andersson KE, Chapple C, et al.
European urology 2016; (70(1)):124-133 doi:10.1016/j.eururo.2015.12.048.
PMID: 26806655 - 15
Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.
Tsubouchi K, Arima H, Abe M, et al.
The Journal of urology 2023; (209(4)):665-674 doi:10.1097/JU.0000000000003209.
PMID: 36787147 - 16
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA, Herschorn S, McVary KT, et al.
The Journal of urology 2020; (203(6)):1163-1171 doi:10.1097/JU.0000000000000738.
PMID: 31895002 - 17
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Yuan JQ, Mao C, Wong SY, et al.
Medicine 2015; (94(27)):e974 doi:10.1097/MD.0000000000000974.
PMID: 26166130 - 18
New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives.
Albisinni S, Biaou I, Marcelis Q, et al.
BMC urology 2016; (16(1)):58 doi:10.1186/s12894-016-0176-0.
PMID: 27629059
This page is for informational purposes only and does not constitute medical advice about your BPH treatment. Your clinician should guide medication changes, fluid restrictions, and safety decisions, including tadalafil use or planned cataract surgery.
Get notified when new evidence is published on benign prostatic hyperplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.